[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583412":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":25,"studyPopulation":29,"armGroups":25,"interventions":30,"overallOfficials":25,"centralContacts":35,"locations":41,"responsibleParty":58,"collaborators":25,"id":60,"slug":25,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":61,"sex":65,"minAge":66,"maxAge":25,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":25,"briefSummary":71,"conditions":72,"keywords":25,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Otsuka Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":25,"otherOutcomes":25},[9,13,16,19,22],{"measure":10,"description":11,"timeFrame":12},"Safety Information (Adverse Event)","Any untoward medicinal occurrence in a patient or clinical study subject administered a Medicinal Product and which does not necessarily have a causal relationship with this treatment (ICH-E2A Guideline). An Adverse Event can therefore be any unfavorable and unintended sign (e.g. abnormal laboratory finding), symptom, or disease temporally associated with the use of a Medicinal Product (brexpiprazole), whether or not it is considered causally related to the Medicinal Product.","24 weeks from the initiation of brexpiprazole treatment",{"measure":14,"description":15,"timeFrame":12},"Safety Information (Special Situations)","Situations related to the use of an Otsuka product which may or may not be associated with an adverse event: -Maternal (pregnancy and breastfeeding) or paternal (via semen) exposure; -Exposure during breastfeeding; -Overdose\u002FIncorrect dosage, misuse, abuse (e.g. patient sharing products); -Medication errors (e.g. patient took wrong dose); -Lack of therapeutic efficacy (e.g. the product doesn't work); -Occupational exposure (e.g.: nurse administering the product is exposed); -Cases of suspected transmission of infectious agents; -Use of suspected or confirmed falsified product(s) or quality defect of the product(s); -Withdrawal reactions; -Accidental exposure (e.g.: child takes parent's product); -Drug-drug\u002Fdrug-food interactions; -Unintentional use of product in a non-approved population (e.g.: pediatric or geriatric population); -Disease progression\u002Fexacerbation of existing disease",{"measure":17,"description":18,"timeFrame":12},"Safety Information (Number of off-Label Use)","Collecting any type of off-Label Use that refers to situations where a product is intentionally used for a medical purpose not in accordance with the authorized product information. Off-label use also includes the intentional use in non-authorized population categories not indicated in the label.",{"measure":20,"description":21,"timeFrame":12},"Safety Information (Serious Adverse Event)","Any adverse drug experience\u002Fevent occurring at any dose which -results in death -is life-threatening -requires inpatient hospitalization or prolonged of existing hospitalization -results in persistent or significant disability or incapacity -is a congenital anomaly\u002Fbirth defect -is medically significant.",{"measure":23,"description":24,"timeFrame":12},"Safety Information (Non-serious Adverse Events)","All Adverse Events that do not meet the definition of a serious Adverse Event are considered non-serious Adverse Events.",null,{"allocation":25,"interventionModel":25,"interventionModelDescription":25,"primaryPurpose":25,"observationalModel":27,"timePerspective":28,"maskingInfo":25},"COHORT","PROSPECTIVE","Patients in Japan who are planned to be newly started on Brexpiprazole OD tablets therapy for the excessive motor activity or physically\u002Fverbally aggressive behavior due to rapid changes in mood, irritability, and\u002For outbursts associated with dementia due to Alzheimer's disease",[31],{"type":32,"name":33,"description":34,"armGroupLabels":25,"otherNames":25},"DRUG","Brexpiprazole (Rexulti)","In general, for adults, start with taking 0.5 mg of brexpirazole at a time, once a day. Then the dose will be increased with an interval of at least one week to 1 mg at a time, once a day. If you have no problem with tolerability and do not show an adequate response, the dose may be increased to 2 mg at a time, once a day, but the increase should be made at intervals of at least one week.",[36],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd","CONTACT","+81-6-6943-7722","komaniwa.satoshi@otsuka.jp",[42],{"facility":43,"status":44,"city":45,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Pharmacovigilance Department","RECRUITING","Osaka","540-0021","Japan","JP",{"type":50,"coordinates":51},"Point",[52,53],135.50107,34.69379,{"lat":53,"lon":52},[56],{"name":57,"role":38,"phone":39,"phoneExt":25,"email":40},"Study Director",{"type":59,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100583412",false,"NCT06875986","REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically\u002FVerbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and\u002For Outbursts Associated With Dementia Due to Alzheimer's Disease)","Inclusion Criteria:\n\n* Patients diagnosed with Alzheimer's disease\n\nExclusion Criteria:\n\n\\-","ALL","15 Years",{"count":68,"type":69},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.",[73],"Alzheimer Disease","2025-06-27",{"date":76,"type":77},"2025-07-02","ACTUAL",{"date":79,"type":77},"2025-04-17",{"date":81,"type":69},"2028-09-23",{"name":5,"class":6},1]